Therapeutic effect of everolimus (RAD001) in combination with antiangiogenic chemotherapy for gastric cancer in vivo

被引：1
|
作者：
Cejka, D.
Preusser, M.
Sieghart, W.
Strommer, S.
Werzowa, J.
Fuereder, T.
Wacheck, V.
机构：
[1] Med Univ Vienna, Div Expt Oncol On, Vienna, Austria
[2] Med Univ Vienna, Inst Neurol, Vienna, Austria
来源：
EJC SUPPLEMENTS | 2006年 / 4卷 / 12期
关键词：
D O I：
10.1016/S1359-6349(06)70075-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
69
引用
收藏
页码：25 / 25
页数：1
相关论文
共 50 条
  • [41] Combination of antiangiogenic therapy using the mTOR-inhibitor RAD001 and low dose chemotherapy for locally advanced and/or metastatic pancreatic cancer - dose finding study
    Joka, M.
    Pustowka, A.
    Alberter, B.
    Hosius, C.
    May, C.
    Decroix, L.
    Bruns, C.
    ONKOLOGIE, 2010, 33 : 80 - 81
  • [42] mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor
    Lane, Heidi A.
    Wood, Jeanette M.
    McSheehy, Paul M. J.
    Allegrini, Peter R.
    Boulay, Anne
    Brueggen, Joseph
    Littlewood-Evans, Amanda
    Maira, Sauveur-Michel
    Martiny-Baron, Georg
    Schnell, Christian R.
    Sini, Patrizia
    O'Reilly, Terence
    CLINICAL CANCER RESEARCH, 2009, 15 (05) : 1612 - 1622
  • [43] INHIBITION OF AUTOPHAGY ENHANCED THE CELL DEATH INDUCING EFFECT OF EVEROLIMUS (RAD001) IN HUMAN BLADDER CANCER CELLS
    Lin, Yi-Chia
    Lin, Ji-Fan
    Tsai, Te-Fu
    Chen, Hung-En
    Chou, Kuang-Yu
    Hwang, Thomas I. S.
    JOURNAL OF UROLOGY, 2014, 191 (04): : E369 - E369
  • [44] Phase I Study of Sorafenib in Combination With Everolimus (RAD001) in Patients With Advanced Neuroendocrine Tumors (NET)
    Chan, Jennifer A.
    Mayer, Robert J.
    Jackson, Nadine
    Malinowski, Paige
    Regan, Eileen
    Kulke, Matthew H.
    PANCREAS, 2011, 40 (02) : 326 - 326
  • [45] Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors (NET)
    Chan, J. A.
    Mayer, R. J.
    Jackson, N.
    Malinowski, P.
    Regan, E.
    Kulke, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [46] Autophagy controls everolimus (RAD001) activity in mantle cell lymphoma
    Rosich, Laia
    Colomer, Dolors
    Roue, Gael
    AUTOPHAGY, 2013, 9 (01) : 115 - 117
  • [47] Phase I trial of escalating doses of weekly everolimus (RAD001) in combination with docetaxel for the treatment of metastatic breast cancer (MBC)
    Moulder, S. L.
    Rivera, E.
    Ensor, J.
    Gonzalez-Angulo, A.
    Christofanilli, M.
    Booser, D.
    Giordano, S.
    Brewster, A.
    Hortobagyi, G.
    Tran, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [48] Everolimus (RAD001) in the Treatment of Advanced Renal Cell Carcinoma: A Review
    Agarwala, Sanjiv S.
    Case, Scott
    ONCOLOGIST, 2010, 15 (03): : 236 - 245
  • [49] EVEROLIMUS (RAD001) AND THE MTOR PATHWAY IN LOW-GRADE GLIOMAS
    Clarke, Jennifer L.
    Chang, Susan
    Phillips, Joanna
    Molinaro, Annette
    Berger, Mitchel
    Nelson, Sarah
    Haas-Kogan, Daphne
    NEURO-ONCOLOGY, 2014, 16
  • [50] The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo
    Ren, Hui
    Chen, Mingwei
    Yue, Ping
    Tao, Hui
    Owonikoko, Taofeek K.
    Ramalingam, Suresh S.
    Khuri, Fadlo R.
    Sun, Shi-Yong
    CANCER LETTERS, 2012, 325 (02) : 139 - 146
12345